Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.

Arrowhead Pharmaceuticals, Inc.

Analysts fell to the sidelines weighing in on Envista Holdings (NVST) and Arrowhead Pharmaceuticals (ARWR) with neutral ratings, indicating that th...

Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST) and Arrowhead Pharmaceuticals (ARWR)

H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Arrowhead Pharmaceuticals today and set a price target of $120.00. Trucchio cov...

Arrowhead Pharmaceuticals (ARWR) Receives a Rating Update from a Top Analyst

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kyntra Bio (KYNB) and Arrowhead Pharmaceuticals (ARW...

Analysts’ Top Healthcare Picks: Kyntra Bio (KYNB), Arrowhead Pharmaceuticals (ARWR)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arrowhead Pharmaceuticals (ARWR), BioNTech SE (BNTX)...

Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), BioNTech SE (BNTX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CapsoVision, Inc. (CV) and Arrowhead Pharmaceuticals...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ARWR	$66.08	+0.02%	17.41K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ARWR	$66.08	+0.0%	17.41K
3
4
5
6

ARWR

Get Arrowhead Pharmaceuticals, Inc. Data in Excel

Get Arrowhead Pharmaceuticals, Inc. Data in Excel